{"disease":{"id":"palmoplantar-pustulosis","name":"Palmoplantar pustulosis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":3},"drugs":{"marketed":[{"drug_id":"guselkumab","indication_name":"Palmoplantar pustulosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tremfya","generic_name":"GUSELKUMAB","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"p19 subunit of IL-23","drug_class":"Interleukin-23 Antagonist [EPC]","quality_score":10,"revenue":"3600","mechanism":"Guselkumab binds to IL-23's p19 subunit, blocking its interaction with the IL-23 receptor and inhibiting proinflammatory cytokine release."},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe palmoplantar pustulosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe palmoplantar pustulosis in infants and children","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06790940","title":"Construction of a Psoriasis and Psoriatic Arthritis Diagnostic Model Based on Multidimensional Nail Information","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":310,"lead_sponsor_name":"Shanghai Yueyang Integrated Medicine Hospital","has_results":false},{"nct_id":"NCT07219420","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"UCB Biopharma SRL","has_results":false},{"nct_id":"NCT04459507","title":"A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan","phase":"","overall_status":"COMPLETED","enrollment_count":276,"lead_sponsor_name":"Janssen Pharmaceutical K.K.","has_results":false},{"nct_id":"NCT04566471","title":"Palmoplantar Pustulosis and Generalized Pustular Psoriasis: A National Population-based Analysis of Prevalence","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT05174065","title":"Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":176,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT02641730","title":"An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":159,"lead_sponsor_name":"Janssen Pharmaceutical K.K.","has_results":true},{"nct_id":"NCT04015518","title":"A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":152,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT07013201","title":"A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":135,"lead_sponsor_name":"LEO Pharma","has_results":false},{"nct_id":"NCT07530367","title":"A Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Tofacitinib Combined With Imatinib in Patients With Moderate-to-Severe Palmoplantar Pustulosis","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":135,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT04061252","title":"A Study of KHK4827 in Subjects With Palmoplantar Pustulosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Kyowa Kirin Co., Ltd.","has_results":false},{"nct_id":"NCT04451720","title":"Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":119,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT04493424","title":"A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":108,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT04057937","title":"A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT05194839","title":"A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":79,"lead_sponsor_name":"Aristea Therapeutics, Inc.","has_results":true},{"nct_id":"NCT07270003","title":"A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar Pustulosis","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT03633396","title":"A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"Vanda Pharmaceuticals","has_results":true},{"nct_id":"NCT03972280","title":"Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"CSL Behring","has_results":false},{"nct_id":"NCT03988335","title":"A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Aristea Therapeutics, Inc.","has_results":true},{"nct_id":"NCT04572997","title":"Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Kristian Reich","has_results":true},{"nct_id":"NCT01794117","title":"Anakinra for Inflammatory Pustular Skin Diseases","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","has_results":true},{"nct_id":"NCT07428915","title":"Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists","phase":"","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"AI Labs Group S.L","has_results":false},{"nct_id":"NCT07000630","title":"Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis","phase":"NA","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT05710185","title":"Deucravacitinib for the Treatment of Palmoplantar Pustulosis","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":true}],"total":23},"guidelines":[],"source":"Drug Landscape verified database"}